Full Description

AngioDynamics, Inc. (AngioDynamics), incorporated in 1992, is a provider of medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD) and local oncology therapy options for treating cancer, including radiofrequency ablation (RFA), systems, irreversible electroporation (IRE), surgical resection systems and embolization products for treating benign and malignant tumors. The Company designs, develops, manufactures and markets a line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases. The Company operates in three segments: Peripheral Vascular, Access and Oncology/Surgery. On January 12, 2009, the Company completed the acquisition of certain assets of FlowMedica, Inc.

Peripheral Vascular

The Peripheral Vascular segment manages the Company’s Venous, Angiographic, percutaneous transluminal angioplasty (PTA), Drainage, Thrombolytic Targeted Renal Therapy, Micro Access and Transjugular Access product lines. Its venous products consist of VenaCure EVLT products and Sotradecol. The Company’s VenaCure EVLT products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Sotradecol is a treatment of small, uncomplicated varicose veins of the lower extremities, in addition to ablation of the great saphenous vein.

Angiographic products and accessories are used during virtually every peripheral vascular interventional procedure. These products permit interventional physicians to reach targeted locations within the vascular system to deliver contrast media for visualization purposes and therapeutic agents and devices, such as stents or PTA balloons. Angiographic products consist primarily of angiographic catheters, but also include entry needles and guidewires specifically designed for peripheral interventions and fluid management products. The Company manufactures angiographic catheters that are available in more than 500 tip configurations and lengths, either as standard items or made to order, and an advanced guidewire.

The Company’s SOFT-VU technology incorporates a soft, atraumatic tip that is easily visualized under fluoroscopy. The ANGIOPTIC line is distinguished from other catheters because the entire instrument is highly visible under fluoroscopy. The Accu-Vu is a highly visible, accurate sizing catheter used to determine the length and diameter of a vessel for endovascular procedures. The Mariner is a hydrophilic-coated angiographic catheter. The Mariner uses the Company’s Soft-Vu catheter technology to deliver contrast media to anatomy that is difficult to reach. The AQUALiner is a technologically advanced guidewire. This guidewire is used to provide access to difficult to reach locations in interventional procedures requiring a highly lubricious wire. The Company offers uncoated, Teflon-coated and hydrophilic-coated guidewires to support its core angiographic catheter line.

The Company’s PTA dilation balloon catheters include WORKHORSE, a high-pressure, low-profile, non-compliant balloon catheter offered in 54 configurations; WORKHORSE II, a high-pressure, low-profile, non-compliant PTA balloon catheter, and PROFILER, a low-profile, high-pressure, non-compliant, high-visibility balloon catheter. Drainage products percutaneously drain abscesses and other fluid pockets. The Company’s line of drainage products consists of TOTAL ABSCESSION general drainage catheters, and ABSCESSION general and biliary drainage catheters. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The Company’s thrombolytic catheters include PULSE*SPRAY and UNI*FUSE catheters, and SPEEDLYSER, which is used to deliver thrombolytic agents into obstructed dialysis grafts.

The Benephit product line is a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury. Benephit is representative of the Targeted Renal Therapy, which is the delivery of therapeutic agents directly to the kidneys through the renal arteries as an alternative to the standard delivery method of systemic intravenous (IV) infusion to address kidney dysfunction related to a number of conditions, including cardiovascular, endovascular, surgical procedures and diseases. The Company’s micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. The Company’s transjugular liver access set is used to provide access in a transjugular intrahepatic portosystemic shunt (TIPS) procedure.

Access

The Access Strategic Business Unit manages the Company’s Dialysis, Port and peripherally inserted central catheter (PICC) product lines. It markets a line of dialysis products that provide short and long-term vascular access for dialysis patients. It offers a variety of dialysis catheters, including DuraMax catheter, which is the initial dialysis catheter that is fully manufactured by AngioDynamics; SCHON chronic dialysis catheter, which is designed to be self-retaining, deliver high flow rates and provide patient comfort; EVENMORE, a low-profile, end-hole design catheter; DURA-FLOW, a chronic dialysis catheter; SCHON XL, an acute dialysis catheter and LIFEJET F-16 chronic dialysis catheter. The Company purchases some products from Medical Components, Inc. (Medcomp) and resells under its name, including its Schon, Schon XL and Dura-Flow dialysis catheters under a worldwide license. It also purchases its Dynamic Flow catheters under a non-exclusive license from Medcomp.

Image-guided vascular access (IGVA) involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Delivery to the circulatory system allows drugs to mix with a large volume of blood as compared to intravenous drug delivery into a superficial vessel. IGVA procedures include the placement of PICC lines, implantable ports and central venous catheters (CVCs). The Company’s PICC products include MORPHEUS CT PICC Insertion Kit, which allows its Morpheus CT PICC to be inserted at a patient’s bedside instead of in the hospital radiology suite. The kit was specifically designed for interventional radiologists, nurse practitioners, physician assistants and radiology technicians who perform placement of PICC lines. These PICC lines provide short or long-term peripheral access to the central venous system for intravenous therapy and blood sampling.

Ports are implantable devices utilized for the central venous administration of a variety of medical therapies and for blood sampling and diagnostic purposes. The Company’s port products and accessories include Vortex line of ports, which consists of titanium, plastic and dual-lumen offerings within its family of products, such as Vortex VX, Vortex TR, Vortex LP and Vortex MP; The Smart Port power-injectable port with Vortex technology, which is a type of port that offers the ability for a clinician to access a vein for both the delivery of medications or fluids and for administering power-injected contrast to perform a Computed Tomography (CT) scan, and the LifeGuard Safety Infusion Set and The LifeGuard Vision, which are used to infuse its ports. The Company’s central venous catheter products include Neostar.

Oncology/Surgery

Oncology/Surgery includes the Company’s RFA, Embolization and IRE product lines. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The RFA system consists of a radiofrequency generator and a family of disposable devices. The Company also markets the HABIB 4X resection device under a distribution agreement with EMcision Limited. In addition to the intra-operative (open surgery) device HABIB 4X, AngioDynamics markets a minimally-invasive version of the HABIB 4X device, a Laparoscopic 4X unit, specifically indicated for clinical use in minimally invasive laparascopic surgery (MILS) procedures in surgical specialties, such as Hepato-Biliary, GI, Surgical Oncology, Transplant Surgery and Urology (Partial Nephrectomy Resections).

LC Beads are compressible, visibly-tinted N-fil Hydrogel microspheres supplied in pre-prepared single vials. Embolic material is injected into selected vessels to block the blood flow feeding the tumor or malformation, causing it to shrink over time. The Company’s NanoKnife System is a technology platform based on the principles of IRE. IRE is for the surgical ablation of soft tissue. The Nanoknife IRE System consists of two components: a Low Energy Direct Current (LEDC) Generator and needle-like electrode Probes.

The Company competes with Biosphere Medical, Boston Scientific Corporation, Cook Medical, Navilyst Medical, Johnson & Johnson, Inc., C.R. Bard, Integra LifeSciences Corporation, Medical Components, Inc., TeleFlex Medical, Smiths Group plc, EV3, Inc., Covidien, Vascular Solutions and VNUS Medical.